Phase II Results: Ponatinib + Blinatumomab in Ph+ ALL

EP: 1.OPTIC Primary Analysis: a Dose-Optimization Study of 3 Starting Doses of Ponatinib in CML Treatment

Now Viewing

EP: 2.Phase II Results: Ponatinib + Blinatumomab in Ph+ ALL

EP: 3.GIMEMA LAL2116, D-ALBA, Updated Results and Prognostic Impact of IKZF1 in Ph+ ALL

EP: 4.GIMEMA LALl2317: Sequential Chemotherapy and Blinatumomab for Adult ALL

EP: 5.MRD as a Prognostic Indicator in Children and Young Adults with Very High-Risk ALL

Data from the following presentations are discussed:

• Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study. (Short, ASCO 2021 Abstract 7001)
  • Efficacy: 28 patients (currently 38 at the time of this interview) with either newly diagnosed (ND) or relapsed/refractory (R/R) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) were enrolled in the phase II study. 100% of ND patients responded to treatment compared to 88% of R/R patients. A complete molecular response was noted in 86% of enrolled patients (87% in ND vs 86% in R/R patients). A greater treatment benefit was noted in the ND cohort with an estimated 1-year overall survival (OS) and event-free survival rate of 94% and 88%, respectively. This is compared to the 88% and 55% OS and event-free survival rates noted in the R/R patient cohort.
  • Safety: Treatment with ponatinib was well tolerated in both patient cohorts with only grade 1-2 side effects noted. Treatment with ponatinib was not discontinued due to toxicity in any patient.

Sponsorship Support From Takeda. Content Independently Developed by OncLive.